Is there a future for antiviral fusion inhibitors?

被引：64

作者：

Berkhout, Ben ^{[1
]}

Eggink, Dirk ^{[1
,3
]}

Sanders, Rogier W. ^{[1
,2
]}

机构：

[1] Univ Amsterdam, Lab Expt Virol, Dept Med Microbiol, Ctr Infect & Immun Amsterdam CINIMA,Acad Med Ctr, NL-1012 WX Amsterdam, Netherlands

[2] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA

[3] Mt Sinai Sch Med, Dept Microbiol, New York, NY USA

来源：

CURRENT OPINION IN VIROLOGY | 2012年 / 2卷 / 01期

基金：

欧洲研究理事会;

关键词：

HUMAN-IMMUNODEFICIENCY-VIRUS; 6-HELIX BUNDLE FORMATION; TYPE-1 ENTRY INHIBITORS; HIV-FUSION; PEPTIDE INHIBITOR; HEPTAD REPEAT; COILED-COIL; CCR5; ANTAGONIST; MEMBRANE-FUSION; MULTIFUNCTIONAL DOMAINS;

D O I：

10.1016/j.coviro.2012.01.002

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Entry of human immunodeficiency virus type 1 (HIV-1) into cells is mediated by attachment of the envelope glycoproteins, gp120 and gp41, to the CD4 receptor and a chemokine receptor (CCR5 or CXCR4) and subsequent fusion of viral and cellular membranes. Several steps of the entry process can be targeted by drugs. Receptor antagonists prevent virus attachment and fusion inhibitors block conformational changes that are required for membrane fusion. The T20 peptide (Enfuvirtide, Fuzeon), which is homologous to part of the gp41-encoded fusion machinery, is the only clinically approved fusion inhibitor, but over the last decade new generations of T20-like peptides have been developed with improved potency and stability, as well as fusion inhibitors that target alternative gp41 domains. Here, we will review the field of HIV-1 fusion inhibitors.

引用

页码：50 / 59

页数：10

共 119 条

[51] Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1 [J].

Jin, BS ;

Ryu, JR ;

Ahn, K ;

Yu, YG .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (17) :1797-1804

[52] Bioorganic synthesis of a recombinant HIV-1 fusion inhibitor, SC35EK, with an N-terminal pyroglutamate capping group [J].

Kajiwara, Kazumi ;

Watanabe, Kentaro ;

Tokiwa, Rei ;

Kurose, Tomoko ;

Ohno, Hiroaki ;

Tsutsumi, Hiroko ;

Hata, Yoji ;

Izumi, Kazuki ;

Kodama, Eiichi ;

Matsuoka, Masao ;

Oishi, Shinya ;

Fujii, Nobutaka .

BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (23) :7964-7970

[53] Design, Synthesis, and Structure-Activity Relationship of a Novel Series of 2-Aryl 5-(4-Oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 Entry Inhibitors [J].

Katritzky, Alan R. ;

Tala, Srinivasa R. ;

Lu, Hong ;

Vakulenko, Anatoliy V. ;

Chen, Qi-Yin ;

Sivapackiam, Jothilingam ;

Pandya, Keyur ;

Jiang, Shibo ;

Debnath, Asim K. .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (23) :7631-7639

[54] Virus membrane-fusion proteins: more than one way to make a hairpin [J].

Kielian, M ;

Rey, FA .

NATURE REVIEWS MICROBIOLOGY, 2006, 4 (01) :67-76

[55] The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults [J].

Kilby, JM ;

Lalezari, JP ;

Eron, JJ ;

Carlson, M ;

Cohen, C ;

Arduino, RC ;

Goodgame, JC ;

Gallant, JE ;

Volberding, P ;

Murphy, RL ;

Valentine, F ;

Saag, MS ;

Nelson, EL ;

Sista, PR ;

Dusek, A .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (10) :685-693

[56] Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry [J].

Kilby, JM ;

Hopkins, S ;

Venetta, TM ;

DiMassimo, B ;

Cloud, GA ;

Lee, JY ;

Alldredge, L ;

Hunter, E ;

Lambert, D ;

Bolognesi, D ;

Mathews, T ;

Johnson, MR ;

Nowak, MA ;

Shaw, GM ;

Saag, MS .

NATURE MEDICINE, 1998, 4 (11) :1302-1307

[57] Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1 [J].

Kopetzki, Erhard ;

Jekle, Andreas ;

Ji, Changhua ;

Rao, Eileen ;

Zhang, Jun ;

Fischer, Stephan ;

Cammack, Nick ;

Sankuratri, Surya ;

Heilek, Gabrielle .

VIROLOGY JOURNAL, 2008, 5 (1)

[58] T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen [J].

Lalezari, JP ;

Bellos, NC ;

Sathasivam, K ;

Richmond, GJ ;

Cohen, CJ ;

Myers, RA ;

Henry, DH ;

Raskino, C ;

Melby, T ;

Murchison, H ;

Zhang, Y ;

Spence, R ;

Greenberg, ML ;

DeMasi, RA ;

Miralles, GD .

JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (07) :1155-1163

[59] A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy [J].

Lalezari, JP ;

Eron, JJ ;

Carlson, M ;

Cohen, C ;

DeJesus, E ;

Arduino, RC ;

Gallant, JE ;

Volberding, P ;

Murphy, RL ;

Valentine, F ;

Nelson, EL ;

Sista, PR ;

Dusek, A ;

Kilby, JM .

AIDS, 2003, 17 (05) :691-698

[60] A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding [J].

Lin, PF ;

Blair, W ;

Wang, T ;

Spicer, T ;

Guo, Q ;

Zhou, NN ;

Gong, YF ;

Wang, HGH ;

Rose, R ;

Yamanaka, G ;

Robinson, B ;

Li, CB ;

Fridell, R ;

Deminie, C ;

Demers, G ;

Yang, Z ;

Zadjura, L ;

Meanwell, N ;

Colonno, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (19) :11013-11018

← 1 2 3 4 5 6 7 8 9 10 →